DR. TIMOTHY C RODELL, M.D.
Osteopathic Medicine at Midland Ave, Aspen, CO
License number
Colorado 23857
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
201 Midland Ave, Aspen, CO 81611
Phone
(970) 948-5844
Professional information
Dr. Timothy C Rodell, Aspen CO - MD (Doctor of Medicine)
Specialties:
Pulmonology
Address:
201 Midland Ave, Aspen 81611
(970) 948-5844 (Phone), (970) 948-5844 (Fax)
(970) 948-5844 (Phone), (970) 948-5844 (Fax)
Certifications:
Internal Medicine, 1983, Pulmonary Disease, 1986
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of North Carolina At Chapel Hill
Graduated: 1980
U Colo Hlth Scis Ctr
University of North Carolina At Chapel Hill
Graduated: 1980
U Colo Hlth Scis Ctr
Treatment Of Mucositis
US Patent:
6685917, Feb 3, 2004
Filed:
Nov 21, 2001
Appl. No.:
09/993383
Inventors:
Gary J. Rosenthal - Louisville CO
Jeffrey B. Etter - Boulder CO
Timothy C. Rodell - Aspen CO
Wren H. Schauer - Boulder CO
Adrian Samaniego - Louisville CO
Jeffrey B. Etter - Boulder CO
Timothy C. Rodell - Aspen CO
Wren H. Schauer - Boulder CO
Adrian Samaniego - Louisville CO
Assignee:
RxKinetix, Inc. - Louisville CO
International Classification:
A61K 31195
US Classification:
424 49
Abstract:
This present invention provides a therapeutic composition for use in the treatment of mucositis and a method for using such a therapeutic composition. The therapeutic composition includes a pharmaceutical substance effective for treating mucositis formulated with a biocompatible polymer, such as a biocompatible reverse-thermal gelation polymer.
Delivery Vehicle Composition And Methods For Delivering Antigens And Other Drugs
US Patent:
7767197, Aug 3, 2010
Filed:
Jun 22, 2001
Appl. No.:
09/888235
Inventors:
Joan P. Blonder - Lafayette CO, US
Claire M. Coeshott - Denver CO, US
Timothy C. Rodell - Aspen CO, US
Wren H. Schauer - Boulder CO, US
Gary J. Rosenthal - Louisville CO, US
Claire M. Coeshott - Denver CO, US
Timothy C. Rodell - Aspen CO, US
Wren H. Schauer - Boulder CO, US
Gary J. Rosenthal - Louisville CO, US
Assignee:
Endo Pharmaceuticals Colorado LLC - Chadds Ford PA
International Classification:
A61A 31/745, A61A 31/00
US Classification:
424 7817, 424 7818, 424 7819, 424 7831, 4242041
Abstract:
The present invention provides an immunogen composition and methods for using the same for the development of immunity, and particularly at mucosal sites in a mammal, thereby providing immunity at the site of entry for many major pathogenic organisms and also systemic immunity. The immunogen composition includes an antigen, a biocompatible polymer, and a liquid vehicle, with the biocompatible polymer and liquid vehicle being present in such proportions and interacting in such a way that the immunogen composition exhibits reverse-thermal viscosity behaviour. A delivery vehicle composition including a drug other than an antigen is also provided. Methods are provided for delivering the compositions of the invention to a host.
Compositions And Methods For Targeted Ablation Of Mutational Escape Of Targeted Therapies For Cancer
US Patent:
8501167, Aug 6, 2013
Filed:
Jan 17, 2008
Appl. No.:
12/531876
Inventors:
David Apelian - Boonton Township NJ, US
Alex Franzusoff - Denver CO, US
Timothy C. Rodell - Aspen CO, US
Alex Franzusoff - Denver CO, US
Timothy C. Rodell - Aspen CO, US
Assignee:
GlobeImmune, Inc. - Louisville CO
International Classification:
A61K 39/00, A61K 31/131, A61K 31/136, A61K 31/166, A61K 31/167
US Classification:
424 9321, 424 9351, 4241851, 4241921, 4242771, 514257, 514275, 514279, 514280, 514577, 514579, 514617
Abstract:
Provided herein are compositions and methods for targeted ablation of mutational escape in the face of cancer therapeutic agents. Compositions comprising the yeast-based vehicles are used in combination with other cancer therapeutic agents.
Treatment Of Esophagitis
US Patent:
2007001, Jan 18, 2007
Filed:
Sep 22, 2006
Appl. No.:
11/525752
Inventors:
Gary Rosenthal - Louisville CO, US
Jeffrey Etter - Boulder CO, US
Timothy Rodell - Aspen CO, US
Wren Schauer - Boulder CO, US
Adrian Samaniego - Louisville CO, US
Jeffrey Etter - Boulder CO, US
Timothy Rodell - Aspen CO, US
Wren Schauer - Boulder CO, US
Adrian Samaniego - Louisville CO, US
International Classification:
A61K 9/14
US Classification:
424486000
Abstract:
A method for treatment of esophagitis is disclosed in which a therapeutic composition is introduced into the esophagus to contact a mucosal surface within the esophagus. The pharmaceutical composition comprises a reverse-thermal gelation polyoxyalkylene block copolymer, a pharmaceutical substance and a pharmaceutical substance selected from the group consisting of glutathione and a precursor for glutathione biosynthesis.
Treatment Of Proctitis
US Patent:
2007001, Jan 18, 2007
Filed:
Sep 22, 2006
Appl. No.:
11/525983
Inventors:
Gary Rosenthal - Louisville CO, US
Jeffrey Etter - Boulder CO, US
Timothy Rodell - Aspen CO, US
Wren Schauer - Boulder CO, US
Adrian Samaniego - Louisville CO, US
Jeffrey Etter - Boulder CO, US
Timothy Rodell - Aspen CO, US
Wren Schauer - Boulder CO, US
Adrian Samaniego - Louisville CO, US
International Classification:
A61K 38/05, A61K 31/385, A61K 9/14
US Classification:
424486000, 514018000, 514440000
Abstract:
A method for treatment of proctitis is disclosed in which a therapeutic composition is introduced into the rectum to contact a mucosal surface within the rectum. The pharmaceutical composition comprises a reverse-thermal gelation polyoxyalkylene block copolymer, a pharmaceutical substance and a pharmaceutical substance selected from the group consisting of glutathione and a precursor for glutathione biosynthesis.
Compositions And Methods For Eliciting An Immune Response To Escape Mutants Of Targeted Therapies
US Patent:
2010003, Feb 11, 2010
Filed:
Jul 10, 2006
Appl. No.:
12/067802
Inventors:
David Apelian - Denver CO, US
Alex Franzusoff - Denver CO, US
Timothy C. Rodell - Aspen CO, US
Alex Franzusoff - Denver CO, US
Timothy C. Rodell - Aspen CO, US
International Classification:
A61K 39/00, A61K 36/06
US Classification:
4241851, 424 9351, 42419516
Abstract:
Provided herein are cells, vectors and viruses in association with a mutant polypeptide that has emerged in response to a therapeutic or prophylactic agent; compositions comprising such cells, vectors and viruses and methods for their use in eliciting an immune response to the mutant polypeptide. In some examples, the immune response is a cellular immune response.
Treatment Of Mucositis Using N-Acetylcysteine
US Patent:
2007007, Mar 29, 2007
Filed:
Sep 29, 2006
Appl. No.:
11/540357
Inventors:
Gary Rosenthal - Louisville CO, US
Jeffrey Etter - Boulder CO, US
Timothy Rodell - Aspen CO, US
Wren Schauer - Boulder CO, US
Adrian Samaniego - Louisville CO, US
Jeffrey Etter - Boulder CO, US
Timothy Rodell - Aspen CO, US
Wren Schauer - Boulder CO, US
Adrian Samaniego - Louisville CO, US
International Classification:
A61K 31/198, A61K 9/14
US Classification:
424486000, 514562000
Abstract:
This present invention provides a therapeutic composition for use in the treatment of mucositis and a method for using such a therapeutic composition. The therapeutic composition includes a pharmaceutical substance effective for treating mucositis formulated with a biocompatible polymer, such as a biocompatible reverse-thermal gelation polymer.
Treatment Of Mucositis
US Patent:
2004014, Jul 22, 2004
Filed:
Dec 4, 2003
Appl. No.:
10/728277
Inventors:
Gary Rosenthal - Louisville CO, US
Jeffrey Etter - Boulder CO, US
Timothy Rodell - Aspen CO, US
Wren Schauer - Boulder CO, US
Adrian Samaniego - Louisville CO, US
Jeffrey Etter - Boulder CO, US
Timothy Rodell - Aspen CO, US
Wren Schauer - Boulder CO, US
Adrian Samaniego - Louisville CO, US
International Classification:
A61K038/19, A61K038/05, A61K031/198
US Classification:
424/085100, 514/018000, 514/562000
Abstract:
This present invention provides a therapeutic composition for use in the treatment of mucositis and a method for using such a therapeutic composition. The therapeutic composition includes a pharmaceutical substance effective for treating mucositis formulated with a biocompatible polymer, such as a biocompatible reverse-thermal gelation polymer.
Vaccine Delivery
US Patent:
2004025, Dec 23, 2004
Filed:
Apr 21, 2004
Appl. No.:
10/828842
Inventors:
Joan Blonder - Lafayette CO, US
Claire Coeshott - Denver CO, US
Timothy Rodell - Aspen CO, US
Wren Schauer - Boulder CO, US
Gary Rosenthal - Lafayette CO, US
Claire Coeshott - Denver CO, US
Timothy Rodell - Aspen CO, US
Wren Schauer - Boulder CO, US
Gary Rosenthal - Lafayette CO, US
International Classification:
A61K039/00, A61K039/38, A61K045/00, A61K047/00
US Classification:
424/184100
Abstract:
We have developed a vaccine delivery system based on the non-ionic block copolymer, Pluronic®F127 (F127), combined with selected immunomodulators. F127-based matrices are characterized by a phenomenon known as reverse thermogelation, whereby the formulation undergoes a phase transition from liquid to gel upon reaching physiological temperatures. Protein antigens (tetanus toxoid (TT), diphtheria toxoid (DT) and anthrax recombinant protective antigen (rPA) were formulated with F127 in combination with CpG motifs or chitosan, as examples of immunomodulators, and were compared to more traditional adjuvants in mice. IgG antibody responses were significantly enhanced by the F127/CpG and F127/chitosan combinations compared to antigens mixed with CpGs or chitosan alone. In addition, the responses were significantly greater than those elicited by aluminum salts. Furthermore, the functional activity of these antibodies was demonstrated using either in vivo tetanus toxin challenge or an anthrax lethal toxin neutralization assay. These studies suggest that a block-copolymer approach could enhance the delivery of a variety of clinically useful antigens in vaccination schemes.